Kevin Hollevoet

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125

Raffit Hassan, Elad Sharon, Anish Thomas et al. · Cancer · 2014 · 170 citations · Full text

Medicine, Oncology, Pharmacology +17

<i>In Vitro</i> and <i>In Vivo</i> Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

Kevin Hollevoet, Emily Mason‐Osann, Xiufen Liu et al. · Molecular Cancer Therapeutics · 2014 · 100 citations · Full text

Medicine, Oncology, Pharmacology +9

Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma

Kevin Hollevoet, Kristiaan Nackaerts, J. Thimpont et al. · American Journal of Respiratory and Critical Care Medicine · 2010 · 95 citations

Medicine, Oncology, Pathology +17

Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma

Kevin Hollevoet, Kristiaan Nackaerts, Robert C. Gosselin et al. · Journal of Thoracic Oncology · 2011 · 83 citations · Full text

Medicine, Cancer Biology, Oncology +7

The Effect of Clinical Covariates on the Diagnostic and Prognostic Value of Soluble Mesothelin and Megakaryocyte Potentiating Factor

Kevin Hollevoet, Kristiaan Nackaerts, Olivier Thas et al. · CHEST Journal · 2011 · 48 citations

Life Sciences, Biostatistics, Molecular Biology +6